KMT2A-ARHGEF12, a therapy related fusion with poor prognosis.
Assaf N, Liévin R, Merabet F, Raggueneau V, Osman J, Kim R, Garnache F, D'Angiò M, Larghero P, Meyer C, Marschalek R, Rousselot P, Terré C.
Assaf N, et al.
Mol Biol Rep. 2021 Oct;48(10):7021-7027. doi: 10.1007/s11033-021-06621-5. Epub 2021 Aug 12.
Mol Biol Rep. 2021.
PMID: 34383244
Review.